Evidence map›Paper›PMID 25310152›Full record

ArticleMolecules (Basel, Switzerland)2014

Exploration of piperidinols as potential antitubercular agents.

Areej Abuhammad, Elizabeth Fullam, Sanjib Bhakta, Angela J Russell, Garrett M Morris, Paul W Finn, Edith Sim

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Areej AbuhammadDepartment of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK.
Elizabeth FullamDepartment of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK.
Sanjib BhaktaDepartment of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK.
Angela J RussellDepartment of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK.
Garrett M MorrisInhibOx, Oxford Centre for Innovation, New Road, Oxford OX1 1BY, UK.
Paul W FinnInhibOx, Oxford Centre for Innovation, New Road, Oxford OX1 1BY, UK.
Edith SimDepartment of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK. E.Sim@kingston.ac.uk.
Oxford Drug Design (United Kingdom) · GBUniversity of Oxford · GBKingston University · GBUniversity of Jordan · JOUniversity of Warwick · GB

Funding

Medical Research Council G0802079
6 · The paper itself

Abstract

Novel drugs to treat tuberculosis are required and the identification of potential targets is important. Piperidinols have been identified as potential antimycobacterial agents (MIC < 5 μg/mL), which also inhibit mycobacterial arylamine N-acetyltransferase (NAT), an enzyme essential for mycobacterial survival inside macrophages. The NAT inhibition involves a prodrug-like mechanism in which activation leads to the formation of bioactive phenyl vinyl ketone (PVK). The PVK fragment selectively forms an adduct with the cysteine residue in the active site. Time dependent inhibition of the NAT enzyme from Mycobacterium marinum (M. marinum) demonstrates a covalent binding mechanism for all inhibitory piperidinol analogues. The structure activity relationship highlights the importance of halide substitution on the piperidinol benzene ring. The structures of the NAT enzymes from M. marinum and M. tuberculosis, although 74% identical, have different residues in their active site clefts and allow the effects of amino acid substitutions to be assessed in understanding inhibitory potency. In addition, we have used the piperidinol 3-dimensional shape and electrostatic properties to identify two additional distinct chemical scaffolds as inhibitors of NAT. While one of the scaffolds has anti-tubercular activity, both inhibit NAT but through a non-covalent mechanism.

Indexed as

AcetyltransferasesAntitubercular AgentsBinding SitesHumansMolecular ConformationMycobacterium tuberculosisPiperidinesProtein BindingAcetyltransferasesAntitubercular AgentsPiperidines

Identifiers

PMID25310152
PMCPMC6271891
OpenAlexW1988132945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.